JP2010540649A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540649A5
JP2010540649A5 JP2010528066A JP2010528066A JP2010540649A5 JP 2010540649 A5 JP2010540649 A5 JP 2010540649A5 JP 2010528066 A JP2010528066 A JP 2010528066A JP 2010528066 A JP2010528066 A JP 2010528066A JP 2010540649 A5 JP2010540649 A5 JP 2010540649A5
Authority
JP
Japan
Prior art keywords
aliphatic
pharmaceutically acceptable
acceptable salt
treating
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010528066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540649A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/078239 external-priority patent/WO2009045992A2/en
Publication of JP2010540649A publication Critical patent/JP2010540649A/ja
Publication of JP2010540649A5 publication Critical patent/JP2010540649A5/ja
Pending legal-status Critical Current

Links

JP2010528066A 2007-10-03 2008-09-30 c−METタンパク質の阻害剤 Pending JP2010540649A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97730507P 2007-10-03 2007-10-03
PCT/US2008/078239 WO2009045992A2 (en) 2007-10-03 2008-09-30 C-met protein kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2010540649A JP2010540649A (ja) 2010-12-24
JP2010540649A5 true JP2010540649A5 (enExample) 2012-10-18

Family

ID=40512401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010528066A Pending JP2010540649A (ja) 2007-10-03 2008-09-30 c−METタンパク質の阻害剤

Country Status (12)

Country Link
US (1) US8481524B2 (enExample)
EP (1) EP2205589B1 (enExample)
JP (1) JP2010540649A (enExample)
CN (1) CN101990538A (enExample)
AT (1) ATE502935T1 (enExample)
AU (1) AU2008308900A1 (enExample)
CA (1) CA2701124A1 (enExample)
DE (1) DE602008005786D1 (enExample)
ES (1) ES2361650T3 (enExample)
MX (1) MX2010003563A (enExample)
NZ (1) NZ584311A (enExample)
WO (1) WO2009045992A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506381A (ja) * 2008-10-21 2012-03-15 バーテックス ファーマシューティカルズ インコーポレイテッド c−METタンパク質キナーゼ阻害剤
ES2534516T3 (es) 2010-01-07 2015-04-23 E.I. Du Pont De Nemours And Company Compuestos heterocíclicos fungicidas
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US9573881B2 (en) 2012-12-25 2017-02-21 Nippon Soda Co., Ltd. Halogenated aniline and method for producing same
CN103242216A (zh) * 2013-05-07 2013-08-14 兰州梦唐精细化工有限公司 N- Boc -六氢-5-氧代环戊[C]并吡咯的合成方法
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CA2961525A1 (en) 2014-09-16 2016-03-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2539726A1 (en) * 2003-09-24 2005-05-06 Vertex Pharmaceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
US7169781B2 (en) * 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
KR20090007347A (ko) * 2006-03-22 2009-01-16 버텍스 파마슈티칼스 인코포레이티드 증식성 장애의 치료를 위한 c-MET 단백질 키나제 억제제

Similar Documents

Publication Publication Date Title
US11267782B2 (en) Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2α inhibitors
US12077506B2 (en) Indane derivatives as hypoxia inducible factor-2(α) inhibitors
JP6342805B2 (ja) 置換ピラゾロ[3,4−d]ピリミジンおよびその用途
JP6664385B2 (ja) Bub1阻害薬としてのベンジル置換インダゾール類
CA2701959C (en) Inhibitors of kinase activity
JP2012506381A5 (enExample)
JP2016526540A5 (enExample)
US12171741B2 (en) 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
JP2014521688A5 (enExample)
JP2015508092A5 (enExample)
JP2015536997A5 (enExample)
TWI507191B (zh) 含src同源區2蛋白酪胺酸磷酸酶-1增效劑及其治療方法
TW200418855A (en) Indolizine compounds
EA201070783A1 (ru) 1,2,4-оксадизольные соединения для лечения аутоиммунных заболеваний
JP2017524003A5 (enExample)
JP2017523141A5 (enExample)
WO2019043706A1 (en) NOVEL BARBITURIC ACID DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS INHIBITORS OF LEUKOCYTE TRANSMIGRATION, THE TREATMENT OF INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES AND CANCER
US9376432B2 (en) Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma
JP2008538099A5 (enExample)
US12479870B2 (en) Base-modified cytidine nucleotides for leukemia therapy
CN1678310A (zh) 用于治疗良性和恶性肿瘤疾病的含有disorazole及其衍生物的药物
WO2019245444A1 (en) Base-modified cytidine nucleotides for leukemia therapy
OA19743A (en) Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma.